Genmab Announces Financial Results for the First Half of 2022
10/8 17:02
August 10 , 202 2 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2022 Highlights Genmab and AbbVie Inc. (AbbVie) announced topline results for epcoritamab from the Phase 1/2 trial in patients with relapsed/refractory large B-cell lymphoma (LBCL) Genmab announced its...